BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Mucin

March 5, 2015 8:00 AM UTC

Studies in patient samples and mice suggest methyl 6-thio-6-deoxy-α-D-galactopyranoside (TDG) could decrease mucus accumulation in CF patients. In patient sputum samples, TDG exhibited more potent and faster-acting mucolytic activity than N-acetylcysteine. In mice, intranasal TDG caused no systemic or lung toxicity. Next steps could include evaluating TDG in combination with other therapies to alleviate pulmonary pathology in CF models...